177 related articles for article (PubMed ID: 20186624)
1. [Clinicopathological features and prognosis of 68 patients with metastatic ovarian tumors from the gastric cancer].
Zhao JZ; Wang G; Zhang RP; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Feb; 13(2):129-32. PubMed ID: 20186624
[TBL] [Abstract][Full Text] [Related]
2. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
3. The role of cytoreductive surgery for colon cancer metastatic to the ovary.
McCormick CC; Giuntoli RL; Gardner GJ; Schulick RD; Judson K; Ronnett BM; Vang R; Bristow RE
Gynecol Oncol; 2007 Jun; 105(3):791-5. PubMed ID: 17408727
[TBL] [Abstract][Full Text] [Related]
4. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries.
Ayhan A; Guvenal T; Salman MC; Ozyuncu O; Sakinci M; Basaran M
Gynecol Oncol; 2005 Aug; 98(2):235-41. PubMed ID: 15982725
[TBL] [Abstract][Full Text] [Related]
5. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
6. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
Bristow RE; Montz FJ
Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
[TBL] [Abstract][Full Text] [Related]
7. Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer.
Cheong JH; Hyung WJ; Chen J; Kim J; Choi SH; Noh SH
J Surg Oncol; 2004 Jul; 87(1):39-45. PubMed ID: 15221918
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of Krukenberg's tumor.
Kim HK; Heo DS; Bang YJ; Kim NK
Gynecol Oncol; 2001 Jul; 82(1):105-9. PubMed ID: 11426970
[TBL] [Abstract][Full Text] [Related]
9. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
10. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
11. Recurrent micropapillary serous ovarian carcinoma.
Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery for stage IV epithelial ovarian cancer.
Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
[TBL] [Abstract][Full Text] [Related]
13. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
[TBL] [Abstract][Full Text] [Related]
14. Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors.
Jiang R; Tang J; Cheng X; Zang RY
Eur J Surg Oncol; 2009 Jan; 35(1):92-7. PubMed ID: 18632244
[TBL] [Abstract][Full Text] [Related]
15. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
16. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
[TBL] [Abstract][Full Text] [Related]
17. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
[TBL] [Abstract][Full Text] [Related]
19. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
[TBL] [Abstract][Full Text] [Related]
20. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]